glp 1 drugs and ms GLP-1 drug enters trial for progressive multiple sclerosis LC-MS Characterization of GLP-1 Peptides
Description
Dehydration can affect kidney function
Weight loss may continue gradually before plateauing, typically around 12-18 months
Abstract Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) were initially developed for the management of type 2 diabetes, due to their role in enhancing insulin secretion, decreasing glucagon secretion, and delaying gastric emptying
doi: 10.1111/dom.12386
Triple GLP- 1/GIP/Glucagon Receptor Agonists- Retatrutide Retatrutide is being developed as a once-weekly subcutaneous injection of a triple GLP- 1, GIP, and glucagon receptor agonist to treat T2DM [109]
